Succinobucol (Probucol monosuccinate) is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.

在兔全血中，Succinobucol（10, 50, 100 μM）导致胶原蛋白诱导的血小板聚集以剂量依赖的方式减少。Succinobucol（10, 100 μM）显著降低了对X/XO的松弛反应。

在肺转移性乳腺癌小鼠中，通过尾部注射给予Succinobucol（40 mg/kg）显著降低了平均转移结节数。而在大鼠中，通过静脉注射Succinobucol（50、100、150 mg/kg）对心率或MAP均无显著影响。

In the metastatic 4T1 breast cancer cells, Succinobucol, SCB and the PCD polymer (equivalent concentration to SCB) are respectively added to each well with SCB concentrations ranging from 4 ng/mL to 40 μg/mL.

Mice, injected 4T1-luc cells, are treated with Succinobucol (40 mg/kg) by tail injection every three days.